We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biocon and Viatris Draw Complete Response Letter for Bevacizumab BLA
Biocon and Viatris Draw Complete Response Letter for Bevacizumab BLA
The FDA has issued a complete response letter (CRL) to Biocon and Viatris over their biologics license application (BLA) for bevacizumab, a proposed biosimilar of Roche’s blockbuster cancer drug Avastin.